Table E2. Studies from 1998 November 2008 That Focus on Performance of Imaging Modalities for Ovarian Lesion Detection and Characterization

Transcription

1 Table E2. Studies from 1998 November 2008 That Focus on Imaging Modalities for Ovarian Lesion Detection and Characterization No. of No. of Tumor Types and Sensitivity Specificity PPV NPV Accuracy False-Positive Study and Year Modality Patients Tumors FIGO Stages Purpose (%) (%) (%) (%) (%) (%) Reuter et al (86), Benign, 2 LMP, 8 invasive OC, 23 other; and MR imaging in lesion MR imaging stages not patients with clinically suspicious adnexal lesions Alcazar and Jurado (87), Brown et al (88), 1998 Van Vierzen et al (89), 1998 Buckshee et al (90), 1998 Kurtz et al (91), 1999 Valentin L (92), 1999 Timmerman et al (93), Benign (45), LMP (3), invasive Ca (7), others (3): I (4), II (0), III (3), IV (0), transvaginal, and Doppler Benign, 8 LMP, 19 invasive OC CA LMP tumors: 6 stage Ia (6), 2 stage Ic and transvaginal score in lesion scoring system in lesion adnexal Comparison of accuracy of CA 125,, and MR in tumors of LMP MR imaging and Doppler Benign, 8 malignant, other malignant; transvaginal and stages not Doppler in lesion patients with presumed adnexal Benign, 87 invasive OC, 27 metastases, 58 other benign; 35 stage I, 13 stage II, 70 stage III or IV, MR, and CT in lesion 78 MR imaging having OC CT Benign, 5 LMP, 17 different invasive OC, 2 other: 4 scoring systems in Doppler stage I, 1 stage II, 10 lesion stage III, and Doppler, Benign, 8 LMP, 55 invasive OC, 20 subjective evaluation of

2 Schelling et al (94), 2000 Grab et al (95), 2000, Doppler metastases; 17 stage I, by readers with 3 stage II, 27 stage III, varying experience in 8 extrauterine pelvic tumors and Doppler and Dopper Benign, 61 invasive OC; 26 stage I, 10 stage II, 22 stage III, 2 for lesion patients with unclear Benign, 5 LMP, 6 invasive OC, 1 metastases, 13 other; stages not,, MR, and PET asymptomatic adnexal lesions MR imaging PET Hricak et al (96), 2000 Kubik-Huch et al (97), 2000 Combined, MR imaging, and PET Native MR imaging Contrastenhanced MR imaging Benign, 96 invasive OC; stages not, MR imaging complex adnexal CT Benign, 4 invasive CT, MR MR imaging 7 7 OC: 1 stage III, 3 stage and, PET IV PET 7 7 patients with suspicious ovarian lesion van Nagell et al (98), 2000 Sato et al (99), 2000 Guerriero et al (100), 2001 Rieber et al (101), 2001 Transvagninal and Doppler and (transvaginal) power Doppler Benign, 17 invasive OC, 26 other Detection of malignant lesions in screening (26); epithelial: 5 stage population I, 3 stage II, 3 stage III (3) Benign, 22 Detection of malignant invasive OC, 2 lesions in screening metastases, 25 other; population epithelial: 12 stage I, 2 stage II, 3 stage III, Benign, 9 LMP, 62 for invasive OC: 16 stage characterization of persistent adnexal I, 36 stage III (36), 9 in Benign, 12 invasive OC; stages not, MR and, PET MR imaging

3 PET Valentin et al (102), 2001 Fenchel et al (103), 2002 Takemori et al (104), 2002 Huber et al (105), 2002 Combined transvaginal, MR, and PET () and Doppler ; pattern recognition () and Doppler ; logistic regression and Doppler Benign, 11 LMP, 13 pattern invasive OC, 8 other malignant: 12 stage I, other stages not recognition and logistic regression models in Benign, 4 LMP, 7 invasive OC, 1 metastases; 3 stage pt1a, 1 stage pt3b, 3 stage pt3c having adnexal, MR, and PET MR imaging patients with suspicious PET MR imaging LMP; 12 stage Ia, 1 stage Ib and transvaginal Benign, 55 invasive OC, 8 other malignancies; 24 stage MR imaging for preoperative lesion LMP tumors and MR for preoperative lesion characterization MR imaging I or II, 31 stage III or IV Orden et al (106), 2003 Kurjak et al (107), 2003 Tailor et al (108), 2003, transvaginal, and contrastenhanced power Doppler 2D transvaginal 2D transvaginal and Doppler 3D transvaginal, B-mode Doppler 3D transvaginal and 3D power Doppler Benign, 14 invasive OC, 40 LMP; stages not invasive OC: 30 stage Ia, 13 stage Ib contrastenhanced adnexal for detection of stage I OC in Benign, 18 invasive OC, 9 normal ovaries; 8 stage I, 1 stage II, 9 stage III Detection of malignant lesions in screening risk groups

4 Ueland et al (109), 2003 Alcazar et al (110), 2003 Sohaib et al (111), 2003 Itakura et al (148), 2003 Marret et al (113), 2004 D'Arcy et al (114), 2004 Kawahara et al (115), 2004 Lerman et al (116), 2004 Ferrazzi et al (112), 2005 Marret et al (117), 2005 and Doppler Benign, 14 LMP, 39 invasive OC: 33 stage I, 6 stage II, 14 stage III score compared with Doppler imaging for lesion ovarian tumors Comparison of 2D and 3D Doppler for D Doppler Benign, 21 invasive OC; stages not D Doppler characterization of in complex adnexal MR imaging Benign, 19 LMP, 42 invasive OC, 27 other; stages not Benign, 3 LMP, 22 invasive OC, 6 other malignant; stages not MR for lesion patients with complex (with DePriest morphologic score) and Doppler adnexal Doppler Contrastenhanced transvaginal Contrastenhanced power Doppler Benign, 2 LMP, 21 invasive OC: 1 stage I, 3 stage II, 12 stage III, Benign, 3 LMP, 4 invasive OC: 1 stage I, 1 stage II, 2 stage III contrastenhanced characterization, benign vs malignant, in patients with known adnexal contrastenhanced having early OC MR imaging Benign. 4 LMP, 19 MR PET invasive OC: 5 stage I, imaging and PET for 4 stage II, 8 stage III, 2 lesion MR imaging and PET having OC PET/CT Invasive OC, 26 other; stages not Power Doppler Benign, 19 LMP, 1 other malignant, 32 invasive OC: 15 stage I or II, 17 stage III or IV Benign, 2 LMP, 21 invasive OC: 1 stage I, PET/CT for characterization of gynecologic lesions morphologic score characterization, patients with small a visual Power Doppler index

5 Guerriero et al (118), 2005 Alcazar and Castillo (119), 2005 Erdogan et al (120, 2005 Sohaib et al (121), 2005 Testa et al (122), 2005 Bazot et al (123), 2006 Rieck et al (124), 2006 Temma-Asano et al (125), 2006 Balan (126), stage II, 12 stage III, 5 score adnexal Benign, 20 LMP, 19 metastases, 56 Classification of performance Doppler invasive OC: 18 stage I to or II, 38 stage III or IV very low, low, high, or very high risk of OC in adnexal D power Doppler Doppler D and power Doppler Benign, 4 LMP, 41 for invasive OC; 8 stage I, lesion 2 stage II, 12 stage III, 4 adnexal Benign, 21 malignant; stages not Benign, 5 LMP, 23 invasive OC, 1 other; stages not solid component detection in by means of and power Doppler as predictor of malignancy MR imaging and for lesion quantitative Doppler characterization, patients with solid pelvic MR imaging Doppler Benign, 9 other malignant, 6 invasive OC: 5 stage III MR imaging Benign, 23 LMP, 46 MR invasive OC: 19 stage imaging I, 4 stage II, 11 stage III characterization, suspicious adnexal Power Doppler transvaginal (and gray-scale ) Benign, 3 LMP, 7 invasive OC, rest: no surgery; stages not MR imaging Benign, 2 invasive OC: 2 stage Ia or transvaginal Benign, 26 invasive OC, 48 other; stages not To assess grading system for discrimination between benign and malignant pelvic tumors in pelvic MR imaging for imaging of benign ovarian cysts Comparison of performance of, MR, and CT having pelvic pathologic conditions MR imaging CT

6 Engelen et al (127), 2006 Adusumilli et al (128), 2006 Yazbek et al (129), 2006 van Nagell et al (130), 2006 Testa et al (131), 2007 and Doppler TV + (D) + MR Benign, 14 LMP, 23 Comparison of invasive OC, 13 other: 7 stage I, 4 stage II, 8 stage III, 4 performance of pelvic examination,, MR, and CA 125 for preoperative discrimination between benign and malignant pelvic tumors in patients with known pelvic MR imaging Benign, 5 invasive OC, 33 other; stages not and transvaginal Contrastenhanced transvaginal Benign, 5 LMP, 1 other malignant, 8 invasive OC: 1 stage I, 3 stage II, 3 stage III, 1 MR for lesion patients with indeterminate adnexal Comparison of performance of risk of malignancy index and ovarian crescent sign for lesion characterization, patients with ovarian Benign, 25 LMP, 44 invasive OC, 7 other transvaginal in malignant, 68 other screening population benign: 28 stage I, 8 stage II, 8 stage III Benign, 8 LMP, 1 Lesion characterization invasive OC; stages in not with papillary projections Doppler Risum et al (132), 2007 Jokubkiene et al (133), 2007 PET/CT Benign, 49 invasive OC, 8 other malignant; 2 stage I, 6 stage II, 29 stage III, 5 PET/CT Benign, 6 LMP, 18 invasive OC, 3 other 3D vs 2D Doppler and D Doppler malignant: 11 stage I, 3 gray-scale stage II, 7 stage III, patients with pelvic 3D Doppler Yazbek et al (134), 2007 Woodward et al (135), 2007 ()U S and Doppler, Doppler Benign for predicition of suitable candidates (from patients with benign cystic lesions) for laparoscopic surgery Benign, 4 malignant, 1 other malignant; 1 transvaginal for stage II, two stage III, 1 lesion high-, moderate-, and population-risk patients

7 Castelucci et al (136), 2007, Doppler PET/CT Benign, 32 malignant: 11 stage I, 3 stage II, 12 stage III, 6 PET/CT and transvaginal for lesion Sladkevicious et al (137), 2007 Van Calster et al (138), 2007 Guerriero et al (139), 2007 Ulusoy et al (149), 2007 Thomassin- Naggara et al (140), 2008 Booth et al (141), 2008 Guerra et al (142), 2008 Thomassin- Naggara et al (143), 2008 Doppler and Doppler, Doppler Benign, 6 LMP, 18 invasive OC, 3 other malignant; for invasive OC, 5 stage I, 3 stage II, 7 stage III, 3 stage IV D power Doppler (vessel tree morphology) adnexal Benign, 52 LMP, for 127 malignant, 63 other lesion malignant: 33 stage I, 10 stage II, 69 stage adnexal III, 15 Doppler Benign, 7 LMP, 16 invasive OC, 2 other malignant: 3 stage I, 3 Doppler and transvaginal stage II, 17 stage III, Benign, 5 LMP, 94 invasive OC, 7 other malignant; 48 stage I, 3 stage II, 40 stage III, 3 MR imaging Benign, 11 LMP, 16 invasive OC: 16 stage I, 4 stage II, 6 stage III, 1 MR imaging Benign, 20 LMP, 78 invasive OC: stages not MR imaging Benign, 16 LMP, 37 invasive OC, 32 other malignant: stages not MR imaging Benign, 13 LMP, 16 invasive OC: 18 stage I, 4 stage II, 6 stage III, 1 3D power Doppler for lesion patients with indeterminate pelvic risk of malignancy index for lesion characterization, adnexal dynamic contrast-enhanced MR complex 3-T MR characterization and staging in patients with MR for lesion dynamic contrast-enhanced MR

8 Tsili et al (144), 2008 Tsili et al (145), 2008 Dai et al (146), 2008 CT Benign, 6 LMP, 39 invasive OC, 2 other malignant: stages not multidetector CT for lesion characterization for all patients and staging in patients with known adnexal lesions MR imaging Benign, 14 invasive OC, 4 LMP, 5 other malignant; stages not MR imaging and CT for lesion CT adenexal Benign, 5 LMP, invasive OC, 3 other transvaginal, 3D malignant: 13 stage I, 5 power Dopper, MR, stage II, 7 stage III, 1 and PET Doppler MR imaging complex adnexal PET Yamamoto et al PET/CT Benign, 4 LMP, 2 (147), 2008 other malignant, 8 invasive OC: 4 stage I, 4 stage III Zhang et al (150), 2008 CT Benign, 152 invasive OC, 13 other malignant; stages not PET/CT having CT for lesion characterization, patients with adnexal Note. PubMed ( was searched with the following keywords: ovarian OR adnexal OR pelvic combined with MR imaging OR CT OR PET OR ultrasound OR sonography. From 1998 to November 2008, studies in the Englishlanguage literature that report the diagnostic performance of MR imaging, CT, PET, or in ovarian lesion characterization were retrieved, and abstracts were reviewed for report of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy or false-negative findings. Also, retrieved reports were screened for additional citations of studies that were not returned in the PubMed search. LMP = low-malignant-potential tumor, OC = ovarian cancer, 3D = three-dimensional, 2D = twodimensional.